Amphastar Pharmaceuticals, Inc (AMPH)

Etorro trading 970x250

About Amphastar Pharmaceuticals, Inc

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors’ offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Address: 11570 6th Street, Rancho Cucamonga, CA, United States, 91730

Amphastar Pharmaceuticals, Inc News and around…

Latest news about Amphastar Pharmaceuticals, Inc (AMPH) common stock and company :

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
20 Oct, 2021 Yahoo! Finance

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Implied IJT Analyst Target Price: $155
22 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares S&P Small-Cap 600 Growth ETF (IJT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $154.55 per unit.

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
14 Sep, 2021 Yahoo! Finance

With its stock down 7.7% over the past three months, it is easy to disregard Amphastar Pharmaceuticals (NASDAQ:AMPH...

Amphastar Pharmaceuticals to Present at the Wells Fargo 2021 Virtual Healthcare Conference
02 Sep, 2021 FinancialContent
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
17 Aug, 2021 Yahoo! Finance

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Amphastar Pharmaceuticals, inc (AMPH) Q2 2021 Earnings Call Transcript
10 Aug, 2021 FinancialContent

AMPH earnings call for the period ending June 30, 2021.

Amphastar Pharmaceuticals (AMPH) Meets Q2 Earnings Estimates
09 Aug, 2021 Yahoo! Finance

Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021
09 Aug, 2021 FinancialContent
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Did Amphastar Pharmaceuticals' (NASDAQ:AMPH) Share Price Deserve to Gain 31%?
31 Jul, 2021 Yahoo! Finance

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9th, 2021
29 Jul, 2021 FinancialContent
Amphastar Pharmaceuticals (AMPH) to Report Q2 Results: Wall Street Expects Earnings Growth
29 Jul, 2021 Yahoo! Finance

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

18 Key Biopharma Catalysts To Keep An Eye On In Q3
10 Jul, 2021 FinancialContent

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming ...

Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference
15 Jun, 2021 FinancialContent
Here's Why Shareholders May Want To Be Cautious With Increasing Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) CEO Pay Packet
01 Jun, 2021 Yahoo! Finance

Under the guidance of CEO Jack Zhang, Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) has performed reasonably well...

Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
27 May, 2021 FinancialContent
Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary
07 May, 2021 FinancialContent
Amphastar Pharmaceuticals Inc (AMPH) Q1 2021 Earnings Call Transcript
07 May, 2021 FinancialContent

AMPH earnings call for the period ending March 31, 2021.

Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
06 May, 2021 Yahoo! Finance

Amphastar (AMPH) delivered earnings and revenue surprises of 42.11% and 6.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Amphastar Pharmaceuticals Q1 Earnings
06 May, 2021 FinancialContent

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q1 results. Quarterly ...

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021
06 May, 2021 FinancialContent
A Peek Into The Markets: US Stock Futures Gain Ahead Of Manufacturing Data
03 May, 2021 FinancialContent

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones dipped 185 points in the previous ...

Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
03 May, 2021 FinancialContent
Amphastar Pharmaceuticals (AMPH) to Report Q1 Results: Wall Street Expects Earnings Growth
29 Apr, 2021 Yahoo! Finance

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021
29 Apr, 2021 FinancialContent
How The Pieces Add Up: VIOG Targets $239
21 Apr, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P Small-Cap 600 Growth ETF (VIOG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $239.27 per unit.

Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
06 Apr, 2021 FinancialContent
Why Humanigen, uniQure, bluebird bio, Amphastar Are Rallying Monday
29 Mar, 2021 FinancialContent

Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. ...

Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
29 Mar, 2021 FinancialContent

Amphastar Pharmaceuticals, Inc (AMPH) is a NASDAQ Common Stock listed in , ,

970x250